CG Oncology (CGON) vs ImmunityBio (IBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ImmunityBio (IBRX) has outperformed CG Oncology (CGON) over the past year, gaining 189.4% versus a gain of 87.3%. CG Oncology is the larger company by market cap ($7.10 billion vs $6.40 billion), about 1.1 times the size, while ImmunityBio is growing revenue faster (+668.3% vs +254.7%). ImmunityBio converts more of its revenue into profit, with a net margin of -310.2% versus -3985.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CGON | IBRX |
|---|---|---|
| Share price | $79.47 | $6.02 |
| Market cap | $7.10B | $6.40B |
| 1-day change | -2.97% | -8.37% |
| YTD return | +91.40% | +204.04% |
| 1-year return | +87.25% | +189.42% |
| 5-year return | — | -7.38% |
| EPS (TTM) | $-2.76 | $-1.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.04M | $113.29M |
| Revenue growth (YoY) | +254.70% | +668.31% |
| Net income (latest FY) | $-161.00M | $-351.40M |
| Gross margin | — | 99.34% |
| Operating margin | -4722.13% | -226.00% |
| Net margin | -3985.02% | -310.18% |
| 52-week high | $93.95 | $12.43 |
| 52-week low | $37.01 | $1.95 |
| Distance from 52-week high | -15.41% | -51.57% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +38.03% | +136.71% |
| Average volume | 1.24M | 12.97M |
| Shares outstanding | 89.32M | 1.06B |
| Employees | 142 | 684 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IBRX has outperformed CGON by 102.2 percentage points over the past year.
- ImmunityBio is more profitable, keeping -310.2 cents of every revenue dollar as net income versus -3985.0 cents for CG Oncology.
- ImmunityBio grew revenue faster in its latest fiscal year (+668.31% vs +254.70%).
About CG Oncology
CGON stock →CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company's product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 142 employees
About ImmunityBio
IBRX stock →ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 684 employees
CGON vs IBRX FAQ
Which is bigger, CG Oncology or ImmunityBio?
CG Oncology (CGON) is larger, with a market capitalization of $7.10B compared with $6.40B for ImmunityBio (IBRX).
Which stock has performed better over the past year, CGON or IBRX?
IBRX returned +189.42% over the past 12 months, compared with +87.25% for CGON (price return, excluding dividends). Past performance does not predict future results.
Are CG Oncology and ImmunityBio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.